CHANGE Study

  • Research type

    Research Study

  • Full title

    The acceptability to CHildren and young people with Asthma of usiNg GEnetic information to guide treatment

  • IRAS ID

    258873

  • Contact name

    Daniel Hawcutt

  • Contact email

    d.hawcutt@liv.ac.uk

  • Sponsor organisation

    Alder Hey Children's Hospital

  • Duration of Study in the UK

    0 years, 4 months, 30 days

  • Research summary

    CHANGE is a study looking at the acceptability of genetic testing in childhood asthma management to aid in personalisation of treatment. It will also assess who should have access to the data, how data should be collected and the relative importance of data from the views of children and young people, parents/guardians and healthcare professionals.

    Children and young people are not currently included in many aspects of personalised medicine. It is not yet clear what children and young people or their parent/guardian will think about the use of using personal data such as genomic information to guide treatment choices. For a novel diagnostic test to be developed and marketed, it is necessary to ensure that it would be acceptable to both healthy children (and parent/guardian), as well as those already diagnosed with asthma.

    This work would examine the theory (including use of genetic data, data sharing between primary and secondary care, etc) and practical issues (preferred method [blood v saliva], where should the test be done - at GP or in secondary care, how to find out results, etc).

    The CHANGE study aims to undertake a prospective questionnaire-based study of children and young people, parents and healthcare professionals who may be attending outpatient clinic for asthma, are members of the Liverpool YPAG, or who work with patients with asthma at Alder Hey Children's Hospital.

    Based on the input from the different perspectives, MCD (an external company) would develop a test to identify all relevant polymorphisms. It is envisaged that within the timeline of the project an initial prototype identifying key polymorphisms may be available to trial and that result reporting could be adapted to make the reporting both useful to the clinician and understandable to the patient/parent/guardian.

  • REC name

    North West - Greater Manchester Central Research Ethics Committee

  • REC reference

    19/NW/0327

  • Date of REC Opinion

    11 Aug 2019

  • REC opinion

    Further Information Favourable Opinion